|Awarded On||September 14, 2022|
|Title||Reversing Aging Associated Resistance to Cancer Immunotherapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Wen Jiang|
|Cancer Sites||All Sites|
*Pending contract negotiation
The human body undergoes considerable changes as it ages, and the immune system is no exception. Aging of the immune system leads to a decline in the body's overall immune function. There is now growing evidence suggesting that the effectiveness of cancer immunotherapy also diminishes with age. Yet, the exact relationship between immune system aging and the effectiveness of cancer immunotherapy is unclear. Furthermore, identification of a strategy to "rejuvenate" an aging immune system would have significant impact on the treatment of cancer and other human diseases. Our group recently found that aged animals respond to immune checkpoint inhibitors to a lesser extent when compared to young a...